GlassScriptPhysician profile
Jorge Lindenbaum
NPI 1952375198
$21,657.41
in general payments reported to CMS, 2019-2025
44 companies · $4,917 in 2025
The $4,917 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,986 · 2020: $2,178 · 2021: $1,856 · 2022: $1,726 · 2023: $3,506 · 2024: $3,489 · 2025: $4,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,623.36 |
| Education | $288.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,396.12 | 2019-2025 | Nucala, Arexvy |
| Janssen Pharmaceuticals, INC | $3,096.54 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $2,087.56 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,060.18 | 2023-2025 | Caplyta |
| Amgen INC. | $989.12 | 2019-2022 | |
| Novo Nordisk INC | $987.71 | 2019-2024 | Wegovy |
| Alkermes, INC. | $969.18 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $789.56 | 2019-2024 | Saphnelo |
| Otsuka America Pharmaceutical, INC. | $690.63 | 2023-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.97 | 2019-2025 | Jardiance, Cyltezo |
| Vanda Pharmaceuticals INC. | $545.61 | 2023-2025 | Fanapt, Hetlioz |
| Corium, LLC | $488.61 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $476.57 | 2020-2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $439.73 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $421.40 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $395.65 | 2019-2020 | |
| Esperion Therapeutics, INC. | $351.89 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $333.56 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $300.78 | 2020-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $260.03 | 2023 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $223.63 | 2019 | |
| Ironshore Pharmaceuticals INC. | $174.43 | 2019-2024 | |
| Lundbeck LLC | $171.97 | 2023-2025 | Rexulti |
| Tris Pharma INC | $150.40 | 2023-2025 | Dyanavel Xr |
| Astellas Pharma US INC | $142.91 | 2024 | Veozah |
| Lilly USA, LLC | $133.86 | 2023-2025 | Zepbound, Taltz |
| Supernus Pharmaceuticals, INC. | $129.33 | 2023-2025 | Qelbree, Qelbree |
| Amarin Pharma, INC. | $124.80 | 2019 | |
| Gilead Sciences, INC. | $122.04 | 2019 | |
| Pfizer INC. | $113.25 | 2020 | |
| Verona Pharma, INC. | $103.40 | 2025 | Ohtuvayre |
| Collegium Pharmaceutical, INC. | $60.73 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $58.53 | 2025 | Zurzuvae |
| Aurinia Pharma U.S., INC. | $49.58 | 2023 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.45 | 2025 | Rejoyn, Rexulti |
| Almatica Pharma LLC | $31.93 | 2025 | Loreev Xr |
| Inspire Medical Systems, INC. | $26.67 | 2025 | Inspire |
| Organon LLC | $25.53 | 2023 | Hadlima, Renflexis |
| Avion Pharmaceuticals | $22.53 | 2023 | Methylphenidate Hydrochloride |
| Mallinckrodt Hospital Products INC. | $21.90 | 2023 | Acthar |
| Genentech USA, INC. | $17.82 | 2023 | Actemra |
| Neurocrine Biosciences, INC. | $16.19 | 2024 | Ingrezza |
| Neos Therapeutics, LP | $13.99 | 2022 | |
| Janssen Biotech, INC. | $9.14 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Lindenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.